News

Do you want to help support student interns? Apply Now!

As students have shown great interest in the upcoming STEM2VA Summer Internship Program, we at VA Bio-Connect want to continue to invite employers to register as host sites for this great opportunity in providing experiential learning to those interested in the life sciences. With an application close date of Jan 31, 2022. There were over 1000 students interested, with over 350 submissions by the closing date. Students have shown interest in all regions across the Commonwealth of Virginia, with specific student interests in bioengineering (180), medical devices (194), and pharmaceuticals (210) respectively.

 

Currently, over 25 employers including; Atelerix Life Sciences Inc. (Charlottesville/Albemarle), ReAlta Life Sciences and LifeNet Health (Coastal VA), Athari Bio Sciences, Inc. and Polaris Genomics (Northern VA), Tympanogen (Richmond), CytoRecovery (Roanoke), and many others across Virginia have registered to host student interns. Employers are encouraged to register as application reviews have just begun and will continue to mid-March to ensure student award letters are presented to the 100 candidates by March 31, 2022. This extraordinary experience is great for the next generation of life science professionals. If you are interested in hosting a student intern, please register here to receive your link to begin reviewing applications.

Any questions you have before registering, please contact VA Bio-Connect Admin at vbcintern@vabio.org for assistance. We look forward to matching you with qualified candidates.

Recent News

10/11/2024

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast

10/10/2024

RIVANNA initiates multi-site first-in-human study for Accuro XV musculoskeletal imaging system

RIVANNA®, developers of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option executed in 2023 by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

10/09/2024

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients. Situated near